淋巴因子在治疗脆弱拟杆菌引起的实验性腹腔内脓肿中的应用。
Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.
作者信息
Gollapudi S V, Gupta A, Thadepalli H, Perez A
机构信息
Department of Pathology, Charles R. Drew University, Los Angeles, California 90059.
出版信息
Infect Immun. 1988 Sep;56(9):2369-72. doi: 10.1128/iai.56.9.2369-2372.1988.
Abstract
The role of cell-free soluble factors (lymphokines) derived from mitogen-activated splenic cells of mice previously immunized against Bacteroides fragilis was evaluated in the treatment of B. fragilis intra-abdominal abscess (IAA). Neither clindamycin nor lymphokines alone were effective against an established B. fragilis IAA, but the combination of clindamycin and lymphokines decreased the abscess size and bacterial counts in the majority of animals. This suggests that the synergy of lymphokines with clindamycin effects cure of IAA caused by B. fragilis and that lymphokines might have an application as adjuncts to conventional antimicrobial therapy in this setting.
摘要
评估了来自先前针对脆弱拟杆菌免疫的小鼠经丝裂原激活的脾细胞产生的无细胞可溶性因子（淋巴因子）在治疗脆弱拟杆菌腹腔内脓肿（IAA）中的作用。单独使用克林霉素或淋巴因子对已形成的脆弱拟杆菌IAA均无效，但克林霉素和淋巴因子的联合使用在大多数动物中减小了脓肿大小并降低了细菌数量。这表明淋巴因子与克林霉素的协同作用可治愈由脆弱拟杆菌引起的IAA，并且在这种情况下淋巴因子可能作为传统抗菌治疗的辅助手段应用。
相似文献
1
Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.淋巴因子在治疗脆弱拟杆菌引起的实验性腹腔内脓肿中的应用。
Infect Immun. 1988 Sep;56(9):2369-72. doi: 10.1128/iai.56.9.2369-2372.1988.
2
Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
J Antimicrob Chemother. 1984 Dec;14(6):633-40. doi: 10.1093/jac/14.6.633.
3
In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.喹诺酮类药物和克林霉素对小鼠体内脆弱拟杆菌和/或大肠杆菌感染的治疗效果：与体外药敏性的相关性
Antimicrob Agents Chemother. 1993 May;37(5):997-1000. doi: 10.1128/AAC.37.5.997.
4
A soluble suppressor T cell factor protects against experimental intraabdominal abscesses.一种可溶性抑制性T细胞因子可预防实验性腹腔脓肿。
J Clin Invest. 1985 Mar;75(3):1023-7. doi: 10.1172/JCI111763.
5
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.新型喹诺酮类药物莫西沙星对小鼠脆弱拟杆菌所致实验性腹腔脓肿的治疗效果
Chemotherapy. 2004 Jun;50(2):76-80. doi: 10.1159/000077806.
6
Evaluation of temafloxacin in a rat model of intra-abdominal abscess.
J Antimicrob Chemother. 1992 Jun;29(6):687-92. doi: 10.1093/jac/29.6.687.
7
Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.预防性抗生素对脆弱拟杆菌混合感染的影响。
Surg Gynecol Obstet. 1987 Dec;165(6):491-5.
8
Chemotherapy of an experimental Bacteroides fragilis infection in mice.小鼠脆弱拟杆菌感染的实验性化疗
Antimicrob Agents Chemother. 1977 Mar;11(3):435-40. doi: 10.1128/AAC.11.3.435.
9
Synergism between penicillin, clindamycin, or metronidazole and gentamicin against species of the Bacteroides melaninogenicus and Bacteroides fragilis groups.青霉素、克林霉素或甲硝唑与庆大霉素对产黑素拟杆菌和脆弱拟杆菌群各菌种的协同作用。
Antimicrob Agents Chemother. 1984 Jan;25(1):71-7. doi: 10.1128/AAC.25.1.71.
10
Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.地氟沙星（A-56619）和A-56620对实验性诱导的脆弱拟杆菌相关性腹腔内脓肿的治疗评估。
Antimicrob Agents Chemother. 1986 Oct;30(4):574-6. doi: 10.1128/AAC.30.4.574.
引用本文的文献
1
Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies.金诺芬对万古霉素耐药肠球菌的抗毒力活性：体外和体内研究。
Int J Antimicrob Agents. 2020 Mar;55(3):105828. doi: 10.1016/j.ijantimicag.2019.10.009. Epub 2019 Oct 26.
2
Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model.在小鼠腹膜炎模型中泰利霉素（HMR 3647）对肠球菌的疗效。
Antimicrob Agents Chemother. 2000 Dec;44(12):3434-7. doi: 10.1128/AAC.44.12.3434-3437.2000.
3
Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.曲伐沙星治疗幼龄和老龄小鼠实验性拟杆菌感染的疗效。
Antimicrob Agents Chemother. 1997 Sep;41(9):1933-6. doi: 10.1128/AAC.41.9.1933.
4
In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.芦氟沙星和环丙沙星对感染脆弱拟杆菌小鼠T细胞亚群及肿瘤坏死因子产生的体内效应
Antimicrob Agents Chemother. 1993 Aug;37(8):1711-2. doi: 10.1128/AAC.37.8.1711.
本文引用的文献
1
Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
J Infect Dis. 1982 Apr;145(4):561-8. doi: 10.1093/infdis/145.4.561.
2
A novel mitogen released by lipid A-stimulated bone marrow cells.
J Immunol. 1982 May;128(5):2206-8.
3
Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model.腹腔脓肿模型中针对脆弱拟杆菌的T细胞依赖性免疫的证据。
J Clin Invest. 1982 Jan;69(1):9-16. doi: 10.1172/jci110445.
4
Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.抗微生物药物在脆弱拟杆菌所致实验性感染中的相对疗效及关键间隔时间
Arch Surg. 1983 Feb;118(2):181-4. doi: 10.1001/archsurg.1983.01390020037006.
5
Susceptibility of anaerobic bacteria in vitro to 23 antimicrobial agents.厌氧细菌在体外对23种抗菌药物的敏感性
Chemotherapy. 1980;26(5):344-53. doi: 10.1159/000237926.
6
Cellular immunity to Bacteroides fragilis capsular polysaccharide.对脆弱拟杆菌荚膜多糖的细胞免疫
J Exp Med. 1982 Apr 1;155(4):1188-97. doi: 10.1084/jem.155.4.1188.
7
Simplified, accurate method for antibiotic assay of clinical specimens.临床标本抗生素检测的简化、准确方法。
Appl Microbiol. 1966 Mar;14(2):170-7. doi: 10.1128/am.14.2.170-177.1966.
8
Anaerobic infections. 1.厌氧感染。1.
N Engl J Med. 1974 May 23;290(21):1177-84. doi: 10.1056/NEJM197405232902106.
9
Abdominal trauma, anaerobes, and antibiotics.腹部创伤、厌氧菌与抗生素。
Surg Gynecol Obstet. 1973 Aug;137(2):270-6.
10
In vivo effects of concanavalin A. I. Immunosuppressive effects.
Transplantation. 1972 Jul;14(1):91-5. doi: 10.1097/00007890-197207000-00013.
Zotero 插件